Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

type I receptor kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (2) Apoptosis (1) Bcr-Abl (1) c-Kit (2) c-Met/HGFR (1) Calcium Channel (2) EGFR (2) ERK (2) IFNAR (1) Isotope-Labeled Compounds (1) JAK (1) mRNA (1) Organoid (4) PACAP Receptor (2) PDGFR (2) PKC (1) Reactive Oxygen Species (ROS) (2) Reference Standards (3) SARS-CoV (1) TGF-beta/Smad (2) TGF-β Receptor (17)
By Research Areas:	Cancer (20) Infection (2) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (2)
Oligonucleotides:	Interferon & Receptors (1) mRNA (1)

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: C-type Lectin-like Receptors (CTLRs) PCSK9 Scavenger Receptor Class B type I (SR-BI）

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-10432

A 83-01 Maximum Cited Publications 129 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-13012

RepSox 20+ Cited Publications E-616452; SJN 2511	Organoid TGF-β Receptor	Metabolic Disease
RepSox (E-616452) is a potent and selective *transforming growth factor-beta receptor* I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀** value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-13226

Galunisertib 65+ Cited Publications LY2157299	TGF-β Receptor	Cancer
Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-P0221

PACAP (1-38), human, ovine, rat 5 Publications Verification Pituitary Adenylate Cyclase Activating Polypeptide 38	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Infection Neurological Disease
PACAP (1-38), human, ovine, rat is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat increases the α-secretase activity. PACAP (1-38), human, ovine, rat elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat can be used for neurotrophic and neuroprotective research .

HY-10432A

A 83-01 sodium Maximum Cited Publications 129 Publications Verification	Organoid TGF-β Receptor	Cancer
A 83-01 sodium is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-16712

LDN-214117 2 Publications Verification	TGF-β Receptor	Cancer
LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC₅₀ value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC₅₀ value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) .

HY-78349

A 77-01 2 Publications Verification	TGF-β Receptor	Cancer
A 77-01 is a potent inhibitor of transforming growth factor (TGF)-β type I receptor superfamily *activin-like kinase* ALK5 with an IC₅₀** of 25 nM .

HY-18758

IN-1130 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 is a highly selective *transforming growth factor-β type* I receptor kinase (ALK5) inhibitor with an IC₅₀ of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC₅₀*=36 nM) and p38α mitogen-activated protein kinase* (IC₅₀=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-128437

TGFβ-IN-5 1 Publications Verification	TGF-β Receptor	Inflammation/Immunology
TGFβ-IN-5 is a type I transforming growth factor-β receptor (TGF-β R1) kinase inhibitor with an IC₅₀ value of 0.0485 μM. TGFβ-IN-5 reverses the effect of TGF-β-mediated cell activation on the expression of fibrosis-related genes. TGFβ-IN-5 can be used in the research of fibroproliferative diseases .

HY-123450

S116836	Bcr-Abl Apoptosis PDGFR	Cancer
S116836, a potent, orally active BCR-ABL tyrosine kinase inhibitor, blocks both wild-type as well as T315I Bcr-Abl. S116836 arrests the cells in the G0/G1 phase of cell cycle, induces apoptosis, increases ROS production, and decreases GSH production in BaF3/WT and BaF3/T315I cells. S116836 also inhibits SRC, LYN, HCK, LCK and BLK, and receptor tyrosine kinases such as FLT3, TIE2, KIT, PDGFR-β. Antitumor activies . S116836 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10432R

A 83-01 (Standard)	Reference Standards TGF-β Receptor	Cancer
A 83-01 (Standard) is the analytical standard of A 83-01 (HY-10432). This product is intended for research and analytical applications. A 83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, type I nodal receptor ALK4 and type I nodal receptor ALK7, with IC₅₀s of 12 nM, 45 nM and 7.5 nM against the transcription induced by ALK5, ALK4 and ALK7, respectively .

HY-13012R

RepSox (Standard) E-616452 (Standard); SJN 2511 (Standard)	Organoid TGF-β Receptor Reference Standards	Metabolic Disease
RepSox (Standard) is the analytical standard of RepSox. This product is intended for research and analytical applications. RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-13226A

Galunisertib monohydrate	TGF-β Receptor	Cancer
Galunisertib monohydrate is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC₅₀ of 56 nM.

HY-13226R

Galunisertib (Standard) LY2157299 (Standard)	TGF-β Receptor Reference Standards	Cancer
Galunisertib (Standard) is the analytical standard of Galunisertib. This product is intended for research and analytical applications. Galunisertib (LY2157299) is an oral and selective TGF-β receptor type I (TGF-βRI) kinase inhibitor with an IC50 of 56 nM.

HY-W684904

LY550410	TGF-β Receptor	Cancer
LY550410 is a small-molecule ATP-competitive inhibitor against **type I TGF-β receptor kinase*, which contains heteroaryl rings for potent binding to the kinase*-domain active site. LY550410 modulates TGF-β signalling, thereby regulates gene expression and ultimately cell growth. LY550410 is promising for research of cancers .

HY-E70737

KIT T670I Recombinant Human Active Protein Kinase	c-Kit	Cancer
KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT T670I is a mutant of KIT. KIT T670I Recombinant Human Active Protein Kinase is a recombinant KIT T670I protein that can be used to study KIT T670I-related functions .

HY-E70739

KIT V559D/T670I Recombinant Human Active Protein Kinase	c-Kit	Cancer
KIT (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. KIT is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. KIT V559D/T670I is a mutant of KIT. KIT V559D/T670I Recombinant Human Active Protein Kinase is a recombinant KIT V559D/T670I protein that can be used to study KIT V559D/T670I-related functions .

HY-114192

TGFβRI-IN-1	TGF-β Receptor	Cancer
TGFβRI-IN-1 is an oral active and selective *TGFβ receptor* type I (TGFβRI)** kinase inhibitor, with IC₅₀ values of 2 nM and 7.6 μM for TGFβRI and TGFβRII, respectively .

HY-174665

Human IFNAR2 mRNA	mRNA	Cancer
Human IFNAR2 mRNA encodes the human interferon alpha and beta receptor subunit 2 (IFNAR2) protein, a protein that belongs to the type II cytokine receptor family. IFNAR2 is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases, which in turn phosphorylate several proteins, including STAT1 and STAT2.

HY-W707119

RepSox hydrochloride E-616452 hydrochloride; SJN 2511 hydrochloride	TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Metabolic Disease
RepSox hydrochloride is a potent and selective inhibitor of transforming growth factor-β receptor I/activin-like kinase 5 (TGF-β-RI/ALK5). RepSox hydrochloride inhibits ALK5 autophosphorylation with an IC50 value of 4 nM. RepSox hydrochloride can be used in the study of obesity and related metabolic diseases such as type 2 diabetes.

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase ALK5 inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer .

HY-E70834

JAK1(JH1) Recombinant Human Active Protein Kinase	JAK	Cancer
JAK1 is a non-receptor tyrosine kinase that plays a critical role in cell signaling via type I/II cytokines and interferons (IFNs). JAK1(JH1) is a kinase domain. JAK1(JH1) Recombinant Human Active Protein Kinase is a recombinant JAK1(JH1) protein that can be used to study JAK1(JH1)-related functions .

HY-P0221A

PACAP (1-38), human, ovine, rat TFA Pituitary Adenylate Cyclase Activating Polypeptide 38 TFA	PACAP Receptor ERK EGFR Reactive Oxygen Species (ROS) Calcium Channel	Neurological Disease
PACAP (1-38), human, ovine, rat TFA is a PAC₁ receptor agonist. PACAP (1-38), human, ovine, rat TFA binds to PACAP type I receptor, PACAP type II receptor VIP1, and PACAP type II receptor VIP2 with IC₅₀s of 4 nM, 2 nM, and 1 nM, respectively. PACAP (1-38), human, ovine, rat TFA increases the α-secretase activity. PACAP (1-38), human, ovine, rat TFA elevates cytosolic Ca ²⁺, increases proliferation and increases phosphorylation of extracellular regulates kinase (ERK) and the epidermal growth factor receptor (EGFR). PACAP (1-38), human, ovine, rat TFA demonstrates potent, efficacious, and sustained stimulatory effects on sympathetic neuronal NPY and catecholamine production. PACAP (1-38), human, ovine, rat TFA can be used for neurotrophic and neuroprotective research .

HY-18758R

IN-1130 (Standard)	TGF-β Receptor	Inflammation/Immunology Cancer
IN-1130 (Standard) is the analytical standard of IN-1130. This product is intended for research and analytical applications. IN-1130 is a highly selective transforming growth factor-β type I receptor kinase (ALK5) inhibitor with an IC50 of 5.3 nM for ALK5-mediated Smad3 phosphorylation. IN-1130 inhibits ALK5 phosphorylation of casein (IC50=36 nM) and p38α mitogen-activated protein kinase (IC50=4.3 μM). IN-1130 suppresses renal fibrosis in obstructive nephropathy and blocks breast cancer lung metastasis .

HY-179400

LDN-193688	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad	Others
LDN-193688 (Compound 26) is a ALK2 inhibitor, with IC₅₀ values of 104, 18, 235, 1530, and 1080 nM against ALK1, ALK2, ALK3, ALK4, and ALK5, respectively. LDN-193688 inhibits bone morphogenetic protein 4 (BMP4)-induced phosphorylation of SMAD1/5/8, with an IC₅₀ of 2.6 μM .

HY-E70750

MET F1200I Recombinant Human Active Protein Kinase	c-Met/HGFR	Cancer
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocyte growth factor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions .

HY-P992326

BOT1711	PDGFR	Inflammation/Immunology Cancer
BOT1711 is a human IgG1κ monoclonal antibody targeting PDGFRB/CD140b. PDGFRB/CD140b belongs to type I receptor tyrosine kinases (RTKs), and is mainly expressed in vascular smooth muscle cells, pericytes, fibroblasts, certain mesenchymal stem cells, and tumor stromal cells.

HY-13012S

RepSox-d5 E-616452-d₅; SJN 2511-d₅	Isotope-Labeled Compounds TGF-β Receptor	Metabolic Disease
RepSox-d₅ (E-616452-d₅) is the deuterium labeled RepSox (HY-13012). RepSox (E-616452) is a potent and selective transforming growth factor-beta receptor I/activin like kinase 5 (TGF-β-RI/ALK5) inhibitor. RepSox inhibits ALK5 autophosphorylation with an IC₅₀ value of 4 nM. RepSox can be used for the research of obesity and associated metabolic diseases such as type 2 diabetes .

HY-181165

SB2960	PKC SARS-CoV IFNAR	Infection
SB2960 is a receptor for activated protein C kinase 1 (RACK1) binder with a human K_D of 5.65 μM. SB2960 can promote stress granule (SG) formation and exhibit potent antiviral activity across diverse viral species. SB2960 suppresses viral replication with minimal cytotoxicity by modulating host antiviral immune responses. SB2960 increases the thermal stability of RACK1 and reduces SARS-CoV-2 N protein levels. SB2960 enhances type I interferon (IFN-β) expression and inhibits RIG-I, ISG56, and RANTES expression. SB2960 can be used for the research of virus infection .

Cat. No.	Nombre del producto

HY-L018

TGF-beta/Smad Compound Library	413 compounds
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc. MCE designs a unique collection of 413 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

TGF-beta/Smad Compound Library

413 compounds

The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.

MCE designs a unique collection of 413 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.

Cat. No.	Nombre del producto	Target	Research Area